The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Novartis; Pfizer; Roche; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Novartis; Roche; Taiho Pharmaceutical
Speakers' Bureau - Novartis; Pfizer; Roche; Sanofi; Taiho Pharmaceutical
Research Funding - Jiangsu Hengrui Medicine (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)

A phase I, open-label, nonrandomized, pharmacokinetic study of trifluridine/tipiracil (TAS-102) in Chinese patients with solid tumors.
 
Xicheng Wang
No Relationships to Disclose
 
Jianfeng Zhou
No Relationships to Disclose
 
Yan Li
No Relationships to Disclose
 
Yuping Ge
No Relationships to Disclose
 
Yanping Zhou
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose
 
Chunmei Bai
No Relationships to Disclose